ASCO: Amgen's KRAS drug shows 'modest' efficacy beyond NSCLC

Amgen’s KRAS inhibitor has shown limited efficacy in early testing in patients with cancers outside of the lung. The study linked the high dose of AMG-510 to a response rate of 12% in colorectal cancer patients and found similar efficacy in other solid tumor types.